Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2011-11-08 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is titled 'Eine Research-Publikation der DZ BANK AG' concerning the company Evotec. It contains detailed financial forecasts (2010 actuals, 2011e-2014e estimates), valuation metrics (KGV, EV/EBITDA), investment recommendations ('Kaufen'), and analysis of upcoming events (Q3 results announcement date). This structure is characteristic of an equity research report or investment analysis, which is not explicitly listed as a primary filing type (like 10-K, ER, IR). However, it is a detailed analytical document providing financial context and outlook. Given the options, it is closest to an Investor Presentation (IP) in terms of content depth and forward-looking nature, although it is explicitly a 'Research-Publikation'. Since 'IP' covers detailed presentations for investors focusing on financials and strategy, and this document provides exactly that (forecasts, valuation, investment thesis), it is the most appropriate fit among the provided codes, rather than a general Regulatory Filing (RNS) or a simple Fund Factsheet (FS). The document length is substantial (over 34k chars), ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. FY 2011
2011-11-08 German
Investor Presentation 2011
Investor Presentation Classification · 98% confidence The document contains detailed financial projections (tables with 2011E, 2012E, 2013E estimates), analyst recommendations ('Recommendation: BUY'), performance data, and extensive disclaimers typical of third-party equity research reports. It is not an official regulatory filing (like 10-K, ER, or IR) but rather an analysis *about* a company (Evotec). The presence of analyst contact information, performance metrics, and a focus on future estimates strongly suggests this is an Investor Presentation or a similar research document. Since 'Investor Presentation' (IP) is defined as a detailed presentation focusing on financials, strategy, and market position, and this document clearly functions as a research report providing analysis and forecasts, IP is the most appropriate classification, distinguishing it from a formal company filing.
2011-10-28 English
Unternehmenspräsentation, October 2011
Investor Presentation Classification · 98% confidence The document is explicitly titled "Best in Class Drug Discovery - Evotec Company Presentation" and contains an "Agenda" listing strategic background, discovery alliances, and financial outlook. It is structured with slides, bullet points, and tables detailing partnerships and pipeline status, which are characteristic features of an Investor Presentation (IP). The length (43,345 chars) suggests it is a substantial document, not just a brief announcement (ruling out RPA/RNS based on the 'Menu vs Meal' rule if it were an announcement, but here it appears to be the presentation itself). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER).
2011-10-17 English
Unternehmenspräsentation, Oktober 2011
Investor Presentation Classification · 98% confidence The document text is titled "Best in C g lass Drug Disc - Unternehmenspräsen co y ver ntation" and contains an agenda, slides, and detailed tables describing 'Forschungsallianzen & Entwicklungspartnerschaften' (Research Alliances & Development Partnerships) and a 'Geschäftsmodell' (Business Model). The content is highly structured, uses presentation formatting (like headers and tables), and focuses on strategy, partnerships, and financial outlook, dated October 2011. This structure and content strongly indicate an Investor Presentation (IP) or a similar strategic overview document, rather than a formal regulatory filing (like 10-K, ER, or IR). Given the options, 'Investor Presentation' (IP) is the most appropriate classification.
2011-10-17 German
Investor Presentation 2011
Investor Presentation Classification · 99% confidence The document is a detailed research publication from DZ BANK AG concerning the company Evotec. It contains extensive financial tables (P&L, key ratios, historical data), investment recommendations ("Kaufen"), fair value calculations, and analysis of recent corporate events (like the Roche deal). This structure—including forward-looking estimates ('e' for estimates), detailed financial breakdowns, and explicit investment ratings—is characteristic of an equity research report or an investor presentation/supplement, rather than a mandatory regulatory filing like a 10-K or an Earnings Release (ER). It is too detailed and analytical to be a simple Earnings Release (ER) or a Fund Factsheet (FS). While it contains financial data, it is presented as an analyst's view, not the company's official filing. It is not a transcript (CT) or a formal regulatory announcement (RNS). The closest fit among the provided options that captures detailed financial analysis and investment guidance is the Investor Presentation (IP), as these research reports often mirror the depth and structure of investor presentations, providing strategic context alongside financials. However, given the context of financial databases, this is most accurately classified as a comprehensive research report, which often overlaps with Investor Presentations (IP) or Management Discussion & Analysis (MDA) if it were from the company itself. Since it is an external research piece providing deep financial forecasts and investment advice, 'Investor Presentation' (IP) is the most appropriate category for this type of forward-looking, analytical document, even though it's technically a research note. Revisiting the definitions: It is not a 10-K (Annual Report), not an ER (initial release), and not an IR (Interim Report). It is an analyst's deep dive. 'IP' (Investor Presentation) covers detailed presentations focusing on financials and strategy, which aligns well with the content structure (financial tables, valuation, investment thesis).
2011-10-17 German
Evotec Company presentation - Jefferies 2011 Global Healthcare Conference
Investor Presentation Classification · 98% confidence The document is explicitly titled "Best in Class Drug Discovery - Evotec Company Presentation" and contains an "Agenda" listing strategic background, discovery alliances, and financial outlook. It includes detailed tables outlining partnerships, focus areas, and pipeline status. This structure and content strongly indicate a formal presentation delivered to investors or analysts, rather than a regulatory filing (like 10-K, AR, or ER) or a brief announcement (like RPA or RNS). Therefore, the most appropriate classification is Investor Presentation (IP). The document length (43,413 chars) is substantial, confirming it is a detailed report/presentation, not just an announcement.
2011-09-27 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.